Tianjin Tianyao Pharmaceuticals (600488.SH): Marketing application for dexamethasone API approved
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that it recently received the dexamethasone "Chemical API Marketing Application Approval Notice" issued by the National Medical Products Administration. The drug is mainly used for allergic and autoimmune inflammatory diseases. This approval will further meet the diversified needs of downstream formulation customers, further enrich the company's product portfolio, fully leverage the advantages of API-formulation integration, and help expand the company's business areas.
Tianjin Tianyao Pharmaceuticals (600488.SH) announced that it recently received the "Chemical API Marketing Application Approval Notice" for dexamethasone issued by the National Medical Products Administration. The drug is mainly used for allergic and autoimmune inflammatory diseases. This approval will further meet the diversified needs of downstream formulation customers, further enrich the company's product portfolio, fully leverage the advantages of API-formulation integration, and help expand the company's business areas.
Related Articles

Jiangsu Lianhuan Pharmaceutical (600513.SH): Bilastine API Approved for Marketing

Beijing Konruns Pharmaceutical (603590.SH): The KC1101 project has received a clinical trial notice.

Palo Alto Networks (PANW.US) Q1 Earnings Call: Net addition of approximately 170 platformization deployments in the quarter! AI vulnerability discoveries approach 7 times last year's monthly average, enterprises begin tapping emergency budgets
Jiangsu Lianhuan Pharmaceutical (600513.SH): Bilastine API Approved for Marketing

Beijing Konruns Pharmaceutical (603590.SH): The KC1101 project has received a clinical trial notice.

Palo Alto Networks (PANW.US) Q1 Earnings Call: Net addition of approximately 170 platformization deployments in the quarter! AI vulnerability discoveries approach 7 times last year's monthly average, enterprises begin tapping emergency budgets






